表紙
市場調查報告書

黑色素細胞刺激荷爾蒙受體:開發中產品分析

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 374679
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
黑色素細胞刺激荷爾蒙受體:開發中產品分析 Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 70 Pages
簡介

本報告提供以黑色素細胞刺激荷爾蒙受體為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

黑色素細胞刺激荷爾蒙受體 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Clinuvel Pharmaceuticals Limited
  • Mallinckrodt Plc
  • Palatin Technologies, Inc.
  • Retrophin Inc.
  • SolaranRx, Inc.

藥物簡介

  • afamelanotide
  • AQB-565
  • 腎上腺皮質刺激荷爾蒙
  • cosyntropin
  • CUV-9900
  • PL-8176
  • PL-8177
  • SRX-1177
  • VLRX-001

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2027TDB

Summary

According to the recently published report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019'; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 9 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H2 2019' outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 6 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders and Oncology which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Uveitis, Vitiligo, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria (Erythropoietic Protoporphyri), Porphyria Variegata, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
  • Aequus BioPharma Inc
  • Clinuvel Pharmaceuticals Ltd
  • Eton Pharmaceuticals Inc
  • Palatin Technologies Inc
  • SolaranRx Inc
  • SynAct Pharma AB
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
  • afamelanotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AP-1189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AQB-565 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • corticotropin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • corticotropin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CUV-9900 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Parvysmelanotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-8177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-9643 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRX-1177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
  • Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 16, 2019: First patient enrolled in Mallinckrodt phase 4 trial of Acthar Gel (Repository Corticotropin Injection) for Severe Keratitis
  • Nov 26, 2019: Data on Acthar Gel (Repository Corticotropin Injection) Therapy in Symptomatic Sarcoidosis published in Therapeutic Advances in Respiratory Disease
  • Nov 12, 2019: Mallinckrodt announces new clinical data evaluating Acthar Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting
  • Nov 11, 2019: SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
  • Nov 07, 2019: Mallinckrodt announces data Publication on the treatment Effectiveness of Acthar Gel (Repository Corticotropin Injection) for resolution of multiple sclerosis relapse in a U.S. Health Plan Population
  • Oct 30, 2019: CLINUVEL: TGA Priority Registration Pathway for Scenesse
  • Oct 17, 2019: Palatin presents on Pl8177 oral colon delivery formulation for Ulcerative Colitis at The 7Th CPC Symposium On Peptide Therapeutics
  • Oct 10, 2019: Clinuvel obtains US approval for rare disorder drug Scenesse
  • Oct 02, 2019: FDA clarifies Scenesse PDUFA Date
  • Oct 01, 2019: Redeye initiates coverage of SynAct Pharma
  • Oct 01, 2019: Mallinckrodt announces positive top-line findings from its observational registry assessing relapse recovery in multiple sclerosis relapse patients treated with Acthar Gel (Repository Corticotropin Injection)
  • Sep 13, 2019: Mallinckrodt analysis suggests Acthar Gel may be a cost-effective option compared to other late-line, adult treatments for Multiple Sclerosis Relapse
  • Sep 10, 2019: SCENESSE presented at ICPP in Milan
  • Aug 06, 2019: Palatin Technologies to present data on anti-inflammatory drug PL-8177 at Canaccord Genuity's 39th Annual Growth Conference
  • Jul 17, 2019: Mallinckrodt ends Acthar Gel's Phase IIb trial in ALS
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aequus BioPharma Inc, H2 2019
  • Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2019
  • Pipeline by Eton Pharmaceuticals Inc, H2 2019
  • Pipeline by Palatin Technologies Inc, H2 2019
  • Pipeline by SolaranRx Inc, H2 2019
  • Pipeline by SynAct Pharma AB, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top